Table 1.
Patients’ demographics and clinical characteristics according to the studied groups.
| ATN | Active ABMR | p-value | Normal | Chronic active ABMR | p-value | |
|---|---|---|---|---|---|---|
| N | 11 | 10 | 12 | 10 | ||
| Biopsy follow-up (POD)a | 9 (6–48) | 10 (5–144) | 0.456 | 100 (84–110) | 2,004 (231–4,607) | <0.001 |
| Serum creatinine at biopsy (μmol/L)a | 299.7 (137.0–754.5) | 294.2 (65.8–806.4) | 0.439 | 121.6 (62.2–134.6) | 179.4 (142.8–376.7) | <0.001 |
| Age (years)a | 48 (39–74) | 39 (26–64) | 0.078 | 53 (35–68) | 46 (27–60) | 0.080 |
| Male, N (%) | 9 (82) | 8 (80) | 1.000 | 8 (67) | 9 (90) | 0.323 |
| No. of transplants (second/third/fourth) | 9/2/0 | 7/2/1 | 0.547 | 10/2/0 | 6/3/1 | 0.361 |
| Dialysis vintage (months)a,b | 58 (37–238) | 58 (26–154) | 0.778 | 55 (11–103) | 58 (13–232) | 0.872 |
| PRA max, N (%)a | 10 (0–90) | 75 (20–98) | 0.022 | 19 (2–96) | 80 (2–98) | 0.050 |
| Anti-HLA class I and/or II positive, N (%)c | 10 (91) | 10 (100) | 1.000 | 8 (44) | 10 (100) | 0.096 |
| DSA class I and/or II positive, N (%)c | 6 (55) | 9 (90) | 0.149 | 0 (0) | 5 (50) | 0.01 |
| Anti-MICA positive, N (%)c | 0 (0) | 3 (30) | 0.090 | 1 (8.3) | 3 (33.3) | 0.272 |
| Induction, N | 0.543 | 0.244 | ||||
| None | 0 | 0 | 0 | 1 | ||
| Basiliximab/daclizumab | 1 | 0 | 0 | 1 | ||
| ATG | 7 | 8 | 12 | 7 | ||
| ATG, rituximab | 3 | 2 | 0 | 1 | ||
| Donors’ age (years)a | 63 (39–73) | 50 (35–58) | 0.024 | 55 (36–65) | 52 (7–65) | 0.372 |
| Donor type (D), N (%) | 11 (100) | 10 (100) | 1.000 | 11 (92) | 9 (90) | 1.000 |
| Male, N (%) | 5 (46) | 6 (60) | 0.670 | 8 (67) | 7 (70) | 1.000 |
| ECD, N (%) | 6 (55) | 3 (33) | 0.387 | 4 (33.3) | 6 (66.7) | 0.198 |
| CIT (h)a | 14.3 (9.1–23.2) | 16.2 (10.3–20.6) | 0.573 | 14.9 (3.4–20.5) | 18.4 (0–23) | 0.118 |
| Mismatchesa | 2 (0–6) | 4 (2–6) | 0.029 | 3 (0–5) | 4.5 (2–6) | 0.008 |
ABMR, antibody-mediated rejection; PRA, panel-reactive antibodies; HLA, human leukocyte antigen; DSA, donor-specific antibodies; MICA, major histocompatibility complex class I chain-related antigen A; ATG, anti-thymocyte globulin; D, deceased; ECD, expanded criteria donor; CIT, cold ischemia time.
a
Data are presented as median (minimum–maximum).
b
Total time on dialysis.
c
At the time of biopsy.